RELLINGEN, GERMANY – Viromed Medical AG, a medical technology company specializing in cold plasma technology, announced on March 23, 2026, that it has received funding approval from the Federal Ministry of Research, Technology and Space for research and development projects. The certification, granted under the Research Allowance Act (FZulG), comprises funding in the high six-figure euro range. This financial backing underscores the scientific and technological relevance of Viromed's solutions and confirms the company's strong innovative capabilities.
The funding will primarily support the further development of two key medical systems: PulmoPlas®, a stationary system designed for integration into ventilation processes, and ViroCap®, a mobile device for contact-free plasma application to support wound healing. PulmoPlas® aims to selectively inactivate pathogenic germs in the lower respiratory tract, offering new therapeutic approaches in intensive care medicine. This application of cold plasma in the lungs represents a novel approach for which no comparable systems currently exist. ViroCap®, on the other hand, focuses on enhancing wound healing through non-contact plasma application. Both projects address critical medical challenges and are expected to expand the current state of the art.
The funding approval highlights Viromed's role as a pioneer in cold plasma technology. According to the company, the development of PulmoPlas® and ViroCap® is being consistently advanced with this financial support, strengthening Viromed's position in the field of non-pharmacological treatment of infectious diseases. The company believes that cold plasma technology offers a promising alternative to traditional antibiotics, particularly in combating drug-resistant pathogens. Viromed Medical AG, listed on the stock exchange since October 2022, operates through its wholly owned subsidiary Viromed Medical GmbH and has a broad customer base in the DACH region and beyond.
For more information, visit www.viromed-medical-ag.de. The original press release is available on www.newmediawire.com.
